➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Merck
McKesson
Mallinckrodt
Moodys
Harvard Business School

Last Updated: October 31, 2020

DrugPatentWatch Database Preview

TEVA Company Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for TEVA
International Patents:813
US Patents:72
Tradenames:476
Ingredients:415
NDAs:701
Patent Litigation for TEVA: See patent lawsuits for TEVA
PTAB Cases with TEVA as petitioner: See PTAB cases with TEVA as petitioner

Drugs and US Patents for TEVA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Pharm AIRDUO DIGIHALER fluticasone propionate; salmeterol xinafoate POWDER;INHALATION 208799-006 Jul 12, 2019 RX Yes No 9,731,087   Start Trial Y   Start Trial
Teva Branded Pharm AUSTEDO deutetrabenazine TABLET;ORAL 208082-003 Apr 3, 2017 RX Yes Yes 9,814,708   Start Trial Y   Start Trial
Teva Pharms PRAZOSIN HYDROCHLORIDE prazosin hydrochloride CAPSULE;ORAL 071745-003 Sep 12, 1988 AB RX No No   Start Trial   Start Trial
Teva Pharm AIRDUO DIGIHALER fluticasone propionate; salmeterol xinafoate POWDER;INHALATION 208799-004 Jul 12, 2019 RX Yes No 10,561,808   Start Trial Y   Start Trial
Teva PHENTERMINE HYDROCHLORIDE phentermine hydrochloride CAPSULE;ORAL 088614-001 Apr 9, 1984 DISCN No No   Start Trial   Start Trial
Teva CEPHALEXIN cephalexin TABLET;ORAL 063023-001 Jan 12, 1989 RX No No   Start Trial   Start Trial
Teva Pharm AIRDUO RESPICLICK fluticasone propionate; salmeterol xinafoate POWDER;INHALATION 208799-001 Jan 27, 2017 RX Yes No 10,124,131   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for TEVA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Teva Branded Pharm QVAR 80 beclomethasone dipropionate AEROSOL, METERED;INHALATION 020911-001 Sep 15, 2000 5,766,573   Start Trial
Teva Branded Pharm QVAR 40 beclomethasone dipropionate AEROSOL, METERED;INHALATION 020911-002 Sep 15, 2000 5,695,743   Start Trial
Teva Branded Pharm LOESTRIN 24 FE ethinyl estradiol; norethindrone acetate TABLET;ORAL 021871-001 Feb 17, 2006 5,552,394   Start Trial
Teva AZILECT rasagiline mesylate TABLET;ORAL 021641-001 May 16, 2006 5,532,415   Start Trial
Teva Pharms Usa COPAXONE glatiramer acetate FOR SOLUTION;SUBCUTANEOUS 020622-001 Dec 20, 1996 5,981,589   Start Trial
Teva Branded Pharm PROAIR HFA albuterol sulfate AEROSOL, METERED;INHALATION 021457-001 Oct 29, 2004 8,834,849   Start Trial
Teva Branded Pharm QVAR 40 beclomethasone dipropionate AEROSOL, METERED;INHALATION 020911-002 Sep 15, 2000 5,605,674   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for TEVA drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Delayed-release Tablets 20 mg ➤ Subscribe 2015-06-03
➤ Subscribe Injection 40 mg/mL, 1 mL pre-filled syringe ➤ Subscribe 2014-02-26
➤ Subscribe Tablets 1 mg/0.02 mg and 75 mg ➤ Subscribe 2006-04-17
➤ Subscribe Tablets 0.15 mg/0.02 mg, 0.15 mg/0.025 mg, 0.15 mg/0.03 mg and 0.01 mg ➤ Subscribe 2013-07-10
➤ Subscribe Tablets 0.15 mg/0.03 mg/0.01 mg ➤ Subscribe 2008-01-22
➤ Subscribe for Injection 3.5 mg/vial ➤ Subscribe 2016-10-26
➤ Subscribe Injection 40 mg/mL, 1 mL pre-filled syringe ➤ Subscribe 2014-01-29
➤ Subscribe Tablets 5 mg, 10 mg, 20 mg, 30 mg ➤ Subscribe 2009-11-18
➤ Subscribe Tablets 0.5 mg and 1 mg ➤ Subscribe 2010-05-17
➤ Subscribe Tablets 0.1 mg/0.02 mg and 0.01 mg ➤ Subscribe 2009-11-16
➤ Subscribe Tablets 0.15 mg/0.03 mg ➤ Subscribe 2004-03-29
➤ Subscribe Extended-release Capsule 15 mg and 30 mg ➤ Subscribe 2008-08-11
Premature patent expirations for TEVA

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
  Start Trial   Start Trial

Supplementary Protection Certificates for TEVA Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2768484 122019000091 Germany   Start Trial PRODUCT NAME: KOMBINATION VON DAUNORUBICIN UND CYTARABIN; REGISTRATION NO/DATE: EU/1/18/1308 20180823
0443983 C300445 Netherlands   Start Trial PRODUCT NAME: VALSARTAN, AMLODIPINE EN HYDROCHLOORTHIAZIDE EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; REGISTRATION NO/DATE: EU/1/09/569/001-060 20091016
1613288 PA2011010 Lithuania   Start Trial PRODUCT NAME: FINGOLIMODUM; REGISTRATION NO/DATE: EU/1/11/677/001, 2011 03 17 EU/1/11/677/002, 2011 03 17 EU/1/11/677/003, 2011 03 17 EU/1/11/677/004 20110317
0566709 C300152 Netherlands   Start Trial PRODUCT NAME: TRAMADOLI HYDROCHLORIDUM EN PARACETAMOLUM; NAT. REGISTRATION NO/DATE: RVG 28113 20030115; FIRST REGISTRATION: 359 228-3 2002050405
0812190 05C0033 France   Start Trial PRODUCT NAME: RASAGILINE; NAT. REGISTRATION NO/DATE: EU/1/04/304/001-007 20050221; FIRST REGISTRATION: EU/1/4/304/001-007 20050221
0810209 33/2007 Austria   Start Trial PRODUCT NAME: DARUNAVIR UND DESSEN PHARMAZEUTISCH VERTRAEGLICHE SALZE; REGISTRATION NO/DATE: EU/1/06/380/001 - EU/1/06/380/008 20070212
0166287 SPC/GB96/056 United Kingdom   Start Trial PRODUCT NAME: PANTOPRAZOLE AND ITS SALTS, HYDRATES AND HYDRATES OF ITS SALTS; REGISTERED: SE SE12131 19940506; UK 04889/0010 19960604
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Merck
Mallinckrodt
AstraZeneca
Medtronic
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.